Replicel is a regenerative medicine company developing autologous cell therapies to treat conditions linked to a deficit of healthy cells required for normal healing and function.
The company’s RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, UV-damaged or aged skin, and pattern baldness. RepliCel is also developing a proprietary, next-generation injection device for delivery of its RCH-01 and RCS-01 products that also has use with other dermatological injection procedures.
RepliCel is purpose built to remain a lean, virtual development-stage company partnering with larger companies to commercialize products globally. One such deal is already in place with Shiseido Company, and others will be announced as they are executed.